Market open
AbbVie/$ABBV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Ticker
$ABBV
Sector
Trading on
NYSE
Industry
Biotechnology
Headquarters
Employees
55,000
ISIN
US00287Y1091
Website
AbbVie Metrics
BasicAdvanced
$332B
80.34
$2.34
0.55
$6.29
3.49%
Price and volume
Market cap
$332B
Beta
0.55
52-week high
$218.66
52-week low
$153.58
Average daily volume
9.1M
Dividend rate
$6.29
Financial strength
Current ratio
0.76
Quick ratio
0.485
Long term debt to equity
4,422.845
Total debt to equity
2,021.968
Dividend payout ratio (TTM)
266.46%
Interest coverage (TTM)
6.68%
Management effectiveness
Return on assets (TTM)
8.34%
Return on equity (TTM)
88.40%
Valuation
Price to earnings (TTM)
80.345
Price to revenue (TTM)
5.796
Price to book
233.85
Price to tangible book (TTM)
-3.6
Price to free cash flow (TTM)
21.614
Dividend yield (TTM)
3.35%
Forward dividend yield
3.49%
Growth
Revenue change (TTM)
5.45%
Earnings per share change (TTM)
-30.38%
3-year revenue growth (CAGR)
0.38%
3-year earnings per share growth (CAGR)
-30.53%
3-year dividend per share growth (CAGR)
5.59%
What the Analysts think about AbbVie
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for AbbVie stock.
AbbVie Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AbbVie Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AbbVie News
AllArticlesVideos
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
Barrons·4 hours ago
Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc.(ABBV) of a Class Action Lawsuit and an Upcoming Deadline
GlobeNewsWire·1 day ago
Techbio Pioneer Etcembly Signs Deal With DJS Antibodies, Part of AbbVie, to Accelerate Antibody Discovery Pipeline
Business Wire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market open
Upcoming events
May15
AbbVie
Dividend·Payment
$1.64Per share
FAQs
What’s the current market cap for AbbVie stock?
AbbVie (ABBV) has a market cap of $332B as of May 14, 2025.
What is the P/E ratio for AbbVie stock?
The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 80.34 as of May 14, 2025.
Does AbbVie stock pay dividends?
Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of May 14, 2025, the dividend rate is $6.29 and the yield is 3.49%. AbbVie has a payout ratio of 266.46% on a trailing twelve-month basis.
When is the next AbbVie dividend payment date?
The next AbbVie (ABBV) dividend payment is scheduled for May 15, 2025.
What is the beta indicator for AbbVie?
AbbVie (ABBV) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.